your buddy Sancho Panza agrees buying another company at this time is premature but calling MF phase ll expansion a "pilot study" bench mark is hardly an accurate assessment of all the successful studies that have gone on with IMET's safety and efficacy to date. Nor is GERN in a death spiral. It's prospects never looked better, albeit SP is a POS
didn't you hear the last presentation. Chippy invited the hedge funds to short for another 2 months by his "hit it out of the ball park" all star performance of silence. When looking at the potential, it's a wonder stockholders here are still sane watchhing the SP. Imetelstat is transformational, as JNJ has said, that's not anything new.
This should not be a company secret as we pond critters already know. Seriously, how could biotech companies or cancer researchers like J&J not already fully know and understand? So if they do, why are stockholders kept in the dark? I doubt any of us are content to see Geron clip J&J's coupons and ride their porch into the California sunset. I know I'm not!
Being sarcastic. Lost my humor over a year ago when I watched my investment drop 75% overnight and has YET to recover. With all the FDA serving up Hys fried liver and J&J's $1bil pkg. of band aids for all GERN's booboos behind us now one would have expected GERN's SP to be back over last year's $5.50 price level by 2014 ASH.
THE SP IS AND HAS BEEN A POS! To argue otherwise is just plain paddling on denial.
Oh, I have no pain left in my tail but realize it may be from being amputated by a speeding porch as I was trying to cross the road. The crazy driver was driving so foot loose fast & furious, I didn't see him coming after looking both ways before crossing.
I'm beyond prayer, being polite and wish-fish-full conjecturing. GERON has turned me into a frothy rabid beaver. Just keep your distance as I'm liable to bite anything that gets in my path or throw droppings from my gyrocopter. We all know the MM will take this down as as support & vol. dries up and shorts rotate their position ...26.8mil shares shorted as of close today down 200K from yesterday. Doesn't reflect the shock & terror Jokao nor Joanie de Phew keep squeezing about. Furthermore the way Chipster presents at these press opts is pathetic; one could even suspect he's in cahoots with the hedge fund's dumpster rather than supportive of shareholders interests. The lack of business leadership and communication of future plans to stock holders is disturbing. There are several trials of Imetelstat that they never even speak of and "wait fur it" is wearing thin. Show me the money!
no I actually had some 40-50% gainers in the last 2 weeks but I refuse to post any here. GERN is still my dog.
well when you consider INCY makes daily gains $103 today and is selling snake oil GERON should be at least $309 with a cure. So WHY isn't it?
Long shlong I've been watching and learning since February 2014. I could SCREAM right now. We should be at $10
Scarlet already said on Tuesday's presentation the $35mil was part of the $170mil the company has in cash to date. No change to bottom line.
when he stated previously that ALL patents related to Imet were in Janssen's hands it stands to reason Menlo Park has become a non entity wrt R&D so perhaps a buyout as you say has already been dealt.
I'm tired of being a beaver chewing on the few twigs that management throws my way on occasion. I wouldn't mind being a banker just this once. You have a point BK, something's brewing under the pond's surface and it's not from me passing gas.
Someday, tomorrow , tomorrow, I've bet my bottom dollars that tomorrow the sun will come out tomorrow, tomorrow come what may, it's always a day away...
if anything considering the partial dismissal of the class action suit last week exonerating any exuberance on GERN's previous discussions wrt IMET, one would have expected Dr S to have taken such criticism to task and "promote" a bit instead full disclosure under reserved silence was and still is an issue with management
the only one question that was asked at the end about resistance to the drug was different from the previous presentation at the 17th BIOTECH CEO conference where again the question of the possibility of some sort of fast track would be in the works on Feb 9, 2015 - GERN. SP $2.97
As quoted by Kanak Kanti De's article on that previous presentation
"My opinion of the presentation - given the conspicuous silence at the end - is that Dr Scarlett and Geron both need to get out of the R&D mode and get into the market/commercialize mode. The presentation, solid in scientific data, lacked the sort of marketing language that would interest investors. The company needs to aggressively come up with market comparison studies, product differentiation studies and further development statements, which idea was actually put forward by a commenter in my previous article, but in much more colorful language, as follows:
"Dr. S., if you go to the trouble of taking 60 seconds to bore the audience reading the initial legalize to avoid being sued, then for goodness sake take advantage of it and say things like:
1) We are going to kick jakafi butt because imetelstat cures cancer and does not just treat the symptoms.
2) Imetelstat is a primary and necessary ingredient in any pan-cancer cure...it is not just good for blood cancers. Even though we stopped clinical trials for tumor based cancers.
3) Our 615 patent will also kick butt in RNAi and it was not sold to J&J."
I posted this bfr the presentation and SP started dropping yesterday. Now I'm wondering if he was dealing with J&J last year why he would had even needed to raise the additional equity through share dilution given the fact that J&J was prepared to share costs with milestones payments going fwd. Unlike PCYC's deal that Jokao goes on about ad nauseam, they retained their in house R&D intact where as GERN's seems to have shut it's doors in Menlo Park. It certainly hasn't improved SP and with current prices we'd be 25% higher, close to my in a year later.